The BlueStar Genomic Health Care Index (BDNANTR) tracks the performance of the largest and most liquid companies in the global genomic healthcare industry. This is a modified market cap-weighted index, and only includes companies that generate at least 50% of their revenue from health care therapies based on targeting or the modification of the genetic makeup of cells or uses mRNA, technology platforms that enable the development of genetics-based health care thearpies, or laboratory equipment or services used to test, code, or develop genetics-based health care companies.
